The invention relates to methods of assessing a patient's risk of developing Progressive multifocal leukoencephalopathy (PML).

Disintegrin variants that bind specifically to one or more of 51 and v integrins, such as v1, v3, v5, v6 and v8, but with reduced binding activity to IIb3, are described. Also described are uses of the disintegrin variants for the treatment or prevention of a disease associated with an v integrin or an 51 integrin.

The present invention pertains to a cell culture medium comprising manganese as a media supplement, which was shown to control recombinant protein glycosylation and methods of using thereof. The present invention further pertains to a method of controlling or manipulating glycosylation of a recombinant protein of interest in a large scale cell culture.

Novel and effective anti-fibrosis agents are obtained. An anti-fibrosis agent containing an antagonist for integrin 81 is used. In addition, used is an antagonist containing an anti-integrin 81 antibody that specifically binds to at least one amino acid in a cap subdomain of an integrin 8 chain and a periphery thereof. Also, used is an anti-fibrosis agent containing an anti-integrin 81 antibody that specifically binds to R120 of an integrin 8 chain and a periphery thereof or S132 and a periphery thereof. Note that the above antagonists may each be an anti-integrin 81 antibody capable of binding to any of integrins 81 derived from a human, mouse, and rat.

Biomarkers predictive of responsiveness to integrin beta7 antagonists, including anti-beta7 integrin subunit antibodies, and methods of using such biomarkers are provided. In addition, methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and Crohn's disease are provided. Also provided are methods of using such predictive biomarkers for the treatment of inflammatory bowel diseases including ulcerative colitis and Crohn's disease.

The present invention is directed to ligand like a chimeric antigen receptor (CAR), comprising an antigen binding domain specific for one or more antigens selected from the group consisting of CLA, CD142, CD73, CD49c, CD66c, CD104, CD318 and TSPAN8; cell populations expressing such CARs and the use of the cell populations for cancer therapy.

The present invention relates to bispecific antibody constructs that specifically bind both integrin alpha-V and integrin 5 (e.g., 51) and methods of making and using those constructs to treat cancer or Activated Fibroblasts other pathological conditions involving these integrins.

A novel method to reduce B-cell lymphoma cell migration to and engraftment of the spleen in patients with JAM-C positive B-cell lymphomas is described. In certain aspects, a method for identifying and treating JAM-C positive B-cell lymphoma patients with anti-JAM-C antibodies is provided. Recombinant antibody molecules that specifically bind to JAM-C are also disclosed.

Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with IBD a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (CCR9) inhibitor compound and a therapeutically effective amount of an anti-47 integrin antibody such as vedolizumab. Also provided herein is a kit containing the CCR9 inhibitor compound and anti-47 integrin antibody.

The invention relates to methods of treating stroke comprising administration of a VLA-4 antagonist to a subject after the onset of the stroke, e.g., ischemic stroke (e.g., acute ischemic stroke) or hemorrhagic stroke (e.g., intracerebral hemorrhage), sub-arachnoid hemorrhage, or traumatic brain injury. Kits and articles of manufacture are also described herein.